| Seattle Aac | |
|
6315 36th Ave Sw, Seattle, WA 98126-3009 | |
| (360) 830-6561 | |
| Not Available |
| Full Name | Seattle Aac |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 6315 36th Ave Sw, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346698313 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL60261204 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Seattle Aac 6315 36th Ave Sw, Seattle, WA 98126-3009 Ph: (360) 830-6561 | Seattle Aac 6315 36th Ave Sw, Seattle, WA 98126-3009 Ph: (360) 830-6561 |
News Archive
Almost 50% percent of the population suffers from tooth sensitivity to cold, sweet and hot foods and liquids, according to a nationwide survey of 1,056 adults age 18—65+. Almost half of respondents had tried sensitivity toothpastes, but only about one-third of those found their experience to be positive, noted Larry Fishman, president of Majestic Drug Co., Inc.
An international team of researchers has conducted a study suggesting that individual variation across different strains of betacoronaviruses can alter their stability and pathogenicity profiles.
Patients with more or less severe forms of rheumatoid arthritis (RA) may have the same painful symptoms, but does this mean that the cause of their illness is the same? And therefore that they should all receive the same treatment? Scientists at VIB and Ghent University have demonstrated with their research into inflammasomes that RA should be considered as a syndrome rather than a single disease.
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
In a study published online in Brain on April 1, researchers from Dr. XU Jin's lab at the Institute of Neuroscience of the Chinese Academy of Sciences and their collaborators revealed a new cellular mechanism for amyotrophic lateral sclerosis, suggested a novel therapeutic strategy targeting the RNA degradation pathway, and identified an asthma drug as a potential medication for ALS.
› Verified 5 days ago
Amy L Donaldson, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Autism Ctr, Box 357920, Seattle, WA 98195 Phone: 206-897-1801 | |
Ms. Carol L Ray, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4507 Sunnyside Ave N, Unit D, Seattle, WA 98103 Phone: 206-849-3937 | |
Ms. Linda E Eblen, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4800 Sand Point Way Ne, Mail Stop W-6839, Seattle, WA 98105 Phone: 206-987-6164 | |
Mrs. Genevieve Houdet-cote, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Ms:h4-pmr, Seattle, WA 98101 Phone: 206-341-0461 | |
Daelene King, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9100 5th Ave Ne, Seattle, WA 98115 Phone: 206-526-2662 | |
Molly Beier, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-744-3000 | |
Vassalo Speech And Language Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2300 W Bertona St, Seattle, WA 98199 Phone: 978-444-0321 |